

ASTELLAS' INITIATIVES FOR LIFE SCIENCE ECOSYSTEM IN JAPAN




Yoshitsugu Shitaka, Ph.D.
Chief Scientific Officer (CScO)
Astellas Pharma Inc.
July 30, 2024

Astellas' Initiatives Overcome Barriers for Startups in Drug Discovery

2

- Creating an environment that seamlessly connects the early stages to practical application -




For sustainable support for startup, it is essential to secure government support for various life science startup ecosystem platforms.

Astellas' Open Innovation Initiatives

3

Strategic networking within and between domestic life science ecosystem hubs



Supporting connectivity with global life science ecosystems

Collaboration with International Incubators

- Leveraging our global network, we have initiated the following support:

- ✓ Collaborating with Astellas' researchers at our international sites (MA, CA, WA, UK)
- ✓ SakuLab™ -Cambridge



(Photo credit: Steelblue)

The government needs to provide the opportunity to establish connections among academia/ startups, overseas clinical trial sites and global life science ecosystems for delivering the global reach of drug discovery research originating in Japan.

Collaboration with Biolabs/LabCentral for Global Life Science Ecosystem

4



Press Release

Astellas, BioLabs and Mitsui Fudosan Announce a Collaboration to Enhance the Life Science Ecosystems in Tsukuba and Kashiwa-no-ha, Japan

- Open Innovation Hub Named SakuLab™-Tsukuba will open at the Astellas Tsukuba Research Center -

TOKYO and Boston, MA October 10, 2023 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and BioLabs Global, Inc. (Founder and CEO: Johannes Fruehauf, "BioLabs") and Mitsui Fudosan (TSE: 8801, President and CEO: Takashi Ueda, "Mitsui Fudosan") today announced that they have agreed on a tri-party memorandum of understanding to enhance the life science ecosystem in Tsukuba and Kashiwa-no-ha, Japan, world-renowned science hubs. With this

Astellas become the only pharmaceutical company among five founding sponsors of LabCentral 238 (Cambridge, MA)



Global

- BioLabs
- LabCentral (MA)
- MBC Biolabs (CA)

- ✓ Contributing to life science ecosystems in the United States
- ✓ Hosting events in collaboration with LabCentral in Boston



<Our Goal>

- **Changing the life science ecosystem in Japan**
- **Fostering startups based on pharmaceutical capability**
- **Increasing visibility of Japanese startups**



APPENDIX

Expected Future Government Policies for Startup Life science Ecosystem

6



Supporting various life science startup ecosystem platforms

- For sustainable support for startups, it is essential not only to provide individual startups to financial assistance but also to secure government support for various life science startup ecosystem platforms.



Enhancing funding for startups to enable drug target and lead discovery

- To overcome the 'Valley of Death,' it is essential to strengthen financial support from the government in addition to private sector funding.



Supporting strategic networking within and between domestic life science ecosystem

- Integrated support is needed to promote the development of a continuous life science ecosystem in Japan.



Supporting connectivity with global life science ecosystems

- The government needs to provide the opportunity to establish connections among academia/startups, overseas clinical trial sites and global life science ecosystems for delivering the global reach of research results originating in Japan.